GIPR

Insilico Medicine has selected ISM1354, an AI-designed GIPR antagonist, as a preclinical candidate for obesity and related metabolic diseases. The drug was discovered using the company's generative AI platform, adding to a growing pipeline of machine-learning-designed therapeutics. The move places Insilico among the biotech firms racing to develop GIPR-targeting weight-loss treatments alongside established GLP-1 drugs.